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Abstract
Introduction—We describe the development and validation of the PROMIS Sexual Function
and Satisfaction (PROMIS SexFS) measures version 1.0 for cancer populations.
Aim—To develop a customizable self-report measure of sexual function and satisfaction as part of
the U.S. National Institutes of Health PROMIS® Network.
Methods—Our multidisciplinary working group followed a comprehensive protocol for
developing psychometrically robust patient reported outcome (PRO) measures including
qualitative (scale development) and quantitative (psychometric evaluation) development. We
performed an extensive literature review, conducted 16 focus groups with cancer patients and
multiple discussions with clinicians, and evaluated candidate items in cognitive testing with
patients. We administered items to 819 cancer patients. Items were calibrated using item response
theory and evaluated for reliability and validity.
Main Outcome Measures—The PROMIS Sexual Function and Satisfaction (PROMIS SexFS)
measures version 1.0 include 79 items in 11 domains: interest in sexual activity, lubrication,
vaginal discomfort, erectile function, global satisfaction with sex life, orgasm, anal discomfort,
therapeutic aids, sexual activities, interfering factors, and screener questions.
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Results—In addition to content validity (patients indicate that items cover important aspects of
their experiences) and face validity (patients indicate that items measure sexual function and
satisfaction), the measure shows evidence for discriminant validity (domains discriminate between
groups expected to be different), convergent validity (strong correlations between scores on
PROMIS and scores on conceptually-similar older measures of sexual function), as well as
favorable test-retest reliability among people not expected to change (inter-class correlations from
2 administrations of the instrument, 1 month apart).
Conclusions—The PROMIS SexFS offers researchers a reliable and valid set of tools to
measure self-reported sexual function and satisfaction among diverse men and women. The
measures are customizable; researchers can select the relevant domains and items comprising
those domains for their study.
Keywords
patient-reported outcome measures; sexual function; satisfaction; cancer; quality of life; male and
female sexual dysfunction
Introduction
Cancer and other chronic diseases, as well as their treatments, often have adverse effects on
sexual function including sexual interest, arousal, orgasm, and comfort during
intercourse.1, 2 In addition, chronic diseases can have indirect effects on sexual function by
altering relationships and self-image as a result of experiencing pain, fatigue, disfigurement,
and dependency.1, 3–5 Tools to assess sexual function and satisfaction in a comprehensive,
valid and precise manner are required to develop targeted and effective treatments. A recent
review highlighted the critical need for improved patient-reported outcome measures of
sexual function.6
The National Institutes of Health’s Patient-Reported Outcomes Measurement Information
System® (PROMIS®) Network was created in 2004 to develop standardized, precise, and
valid measures of patient-reported outcomes for use in research across chronic diseases.7
Unique to the PROMIS initiative is the extensive, comprehensive development of its item
banks, i.e., a large set of questions and response options (items) for each measured domain.
PROMIS item banks undergo qualitative evaluation using focus groups, cognitive testing,
and psychometric evaluation incorporating item response theory (IRT). Content represents
substantial input from patients, clinicians, and survey methodologists, making the PROMIS
measures both clinically relevant and valid for research. Finally, PROMIS item banks
provide an unusual degree of flexibility to researchers, allowing them to select relevant
items to accurately measure the domains of interest for their target population. In 2004, the
National Cancer Institute identified sexual function as highly relevant for cancer survivors
and provided support for creating a new measure of sexual function through the PROMIS
network.
Aims
We describe the development and validation of the PROMIS Sexual Function and
Satisfaction (PROMIS SexFS) measures version 1.0 for cancer populations. Our goal was to
develop a customizable self-report set of measures that was a) comprehensive in scope, b)
flexible to meet diverse research needs, c) broadly applicable with respect to age, gender,
sexual orientation, partner status, and literacy level, and d) disease-neutral yet useful across
a wide spectrum of diseases with symptoms that potentially interfere with functioning.
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Our multidisciplinary working group followed the comprehensive PROMIS protocol for
developing psychometrically robust patient reported outcome (PRO) measures.8, 9 The
qualitative steps (scale development) are reported in detail elsewhere6, 10, 11 and described
in brief here. The quantitative steps (psychometric evaluation) are described in detail here.
All patient participants provided informed consent. The Institutional Review Board of the
XXX Health System approved this study.
Scale Development
Review of Extant Items—Using a consensus-driven approach, we conducted a literature
search for articles published from 1991–2007 that reported the administration of a self-
reported measure of sexual function in a cancer population; see Jeffery 2009 for detail.6
Based on this literature review, we developed a preliminary conceptual model to reflect
domains to be included in the measures: interest in sexual activity, lubrication, vaginal
discomfort, erectile function, orgasm, anal discomfort, frequency of sexual activity, and
sexual satisfaction. We categorized more than 1100 items from existing measures into these
domains and selected ~50 clinically relevant items for further testing.
Item banks are dynamic and can incorporate extant items on the same scoring metric. We
incorporated into the PROMIS SexFS some items that are publically available or for which
the copyright holders granted permission. Thus, some PROMIS SexFS instruments include
modified items from other sexual function instruments (e.g., UCLA-Prostate Cancer
Index,12 Female Sexual Function Index [FSFI]13).
Focus Groups—We conducted 16 focus groups with 109 patients to establish the content
validity of the PROMIS SexFS measures.10 Patient focus groups focused on physical and
psychosocial impacts of cancer on sexual function and intimate relationships; see Flynn
2011 for detail. We also discussed the clinical relevance of the proposed conceptual model
with oncology researchers and clinicians and sought their views on how cancer and its
treatment affected patients’ sexual health. We published our working conceptual
measurement model10 and provide an adapted version to show the domains covered and
how they may relate to each other (Figure). We wrote ~40 new items based on the results of
these groups/discussions and added domains describing symptoms and other factors that
interfere with sexual satisfaction.
Cognitive Interviews—To evaluate face validity, we tested items in cognitive interviews.
Each of 83 candidate items was evaluated for clarity, sensitivity, and relevance by 5 or more
participants, at least 2 of whom had less than a 9th grade education or reading level as tested
by the Wide Range Achievement Test 4;14 see Fortune-Greeley 2009 for detail.11 The 39
participants (16 low literacy) were diverse with respect to sex and race as well as cancer
type and stage. Items were revised based on results of the interviews. Substantially revised
items were retested in additional interviews.
Other Qualitative Review—The team responsible for translating all PROMIS measures
reviewed all items and minor changes were made to reduce potential difficulty with
translation to non-English languages.15 We also convened 7 additional clinical and academic
experts on sexual function and cancer to review the conceptual model and item development
to date.
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Study Sample—Patients who participated in item testing were recruited from the Duke
University tumor registry (mailed invitation, 56% of sample), Duke’s private diagnostic
oncology clinics (in person, 14% of sample), as well as the NexCura internet panel (emailed
invitation, 30% of sample). For patients recruited through NexCura, we verified cancer
diagnosis and treatment status with their treating physician. We also targeted recruitment of
additional lesbian, gay, and bisexual cancer patients and survivors through online
communities, though this strategy yielded few participants (n=14). Patients were eligible if
they were 18 years of age or older, had been diagnosed with cancer, and were able to speak
English. We aimed for a diverse sample regarding sex, race, tumor site, and whether the
person was undergoing active treatment for cancer or in post-treatment follow-up (Table 1).
The initial target sample comprised ~250 men and ~250 women, but roughly 40% of this
sample had not been sexually active in the past 30 days. Thus, we recruited a supplemental
sample of ~300 sexually active cancer patients and survivors from the same sources.
Participants completed 2 screener items, 79 PROMIS SexFS items, and 49 items from other
commonly used measures of sexual function (FSFI, UCLA Prostate Cancer Index, Medical
Outcomes Study Sexual Problems Survey,16 International Index of Erectile Function
[IIEF]17).
Analytic Approach—We performed a psychometric evaluation of the SexFS domains of:
Interest in Sexual Activity, Lubrication [women], Vaginal Discomfort [women], Erectile
Function [men], Orgasm, Anal Discomfort, and Global Satisfaction with Sex Life using the
established PROMIS methodology based on classical test theory and IRT.9 We first
examined the distribution of item responses and examined item-total correlations within the
same SexFS domain. Multiple statistical software programs were used, including Mplus
(version 5.21, Muthen & Muthen) and MULTILOG (ver 7.03, Scientific Software
International) as noted below, and SAS software 9.2 (SAS Institute Inc., Cary, NC, USA)
for other analyses. Psychometric analyses were not conducted for the subdomains not
thought to comprise latent variables (Sexual Activities, Interfering Factors, Therapeutic
Aids, and Screener Items).
After adequate distribution of item responses and item-total correlations within the same
SexFS domain being verified were established, confirmatory factor analyses (CFA) were
conducted in Mplus to supply statistics and factor score estimates for evaluating
assumptions applied in IRT modeling, namely unidimensionality, local independence, and
monotonicity. Unidimensionality means that the items measure a common underlying aspect
of functioning. This was tested by examining the fit of a single-factor CFA model for
ordinal categorical item responses.18 For this, multiple indices were computed, including the
comparative fit index (criterion for good fit is >0.95), Tucker-Lewis index (>0.95 for good
fit), and root mean square error of approximation (<0.06 for good fit). When CFA showed a
poor fit, exploratory factor analysis (EFA) was used to explore alternative models. Local
independence requires that there are no significant associations among item responses once
the dominant factor influencing a person’s response to an item is controlled. Item pairs with
high residual correlations (>0.2) were flagged as possible cases of local dependence.
Monotonicity assumes that the probability of endorsing an item response indicative of better
health status should increase as the underlying level of health increases. For each item, we
examined the relationship between the item score and the factor score graphically and via a
polyserial correlation.
Item Calibration—IRT modeling was used to evaluate the psychometric properties of
each item within a scale and to calibrate the metric for the items, i.e., to generate statistical
parameters that allow translations of a person’s item responses into an estimate of that
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person’s underlying functioning. The probability of choosing each item-response category is
modeled as a function of the underlying latent trait, denoted by theta (θ). Samejima’s
Graded Response Models (GRM) was chosen as the primary IRT model, following
PROMIS conventions.19, 20 In the GRM, each item is assigned a set of parameter estimates:
a slope parameter for discrimination and a number of between-category thresholds. Item
characteristic curves, as well as item and test information curves were produced and
examined to ensure adequate properties of items and measures. Scores for each respondent
were calculated based on their responses to each of the items within the SexFS item bank
and rescaled to a T distribution (mean = 50, standard deviation = 10). IRT analysis was
performed by using MULTILOG.
Differential Item Functioning (DIF) and Measurement Invariance—DIF occurs
when people from different groups with the same latent trait have a different probability of
giving a certain response on a question.21 Differences between groups (e.g., males and
females) in individual item behavior were assessed via an analysis of DIF. We tested DIF
for males vs females (on domains that both men and women answered, including Global
Satisfaction with Sex Life and Interest in Sexual Activity) and web- versus phone-based
mode of administration (on all domains). We used ordinal logistic regression to examine
DIF at the item level. An item was classified as displaying DIF if (1) the Likelihood ratio
chi-square test in logistic regression had a p-value ≤ 0.01, and (2) the Zumbo-Thomas effect
size, which is increment of the R-square, was≥ 0.130.22
We also used multiple-group analysis in MPlus to examine measurement invariance at the
domain level. Because our sample size for some DIF analyses was smaller than typically
desired, we also relied on graphical methods, producing item-predicted factor score mean
curves to visually verify the magnitude of the DIF and whether non-uniform DIF exists.
Intra-class correlation coefficients were calculated to assess the agreement between factor
scores generated from group-specific and common IRT parameter estimates.
Concurrent and Construct Validity—To establish concurrent validity, we first
examined Pearson correlation coefficients between subdomains of the PROMIS SexFS and
other widely used measures of conceptually similar constructs, namely the 19-item FSFI13
and the 15-item IIEF.17 Second, we examined whether scores on selected subdomains of the
PROMIS SexFS could discriminate between groups that should, in theory, differ in terms of
their sexual experiences. During item testing, participants were asked whether they had ever
asked an oncology professional about sexual problems. We hypothesized that asking for
help with sexual problems may indicate a clinically meaningful decrement in function.
Reliability Analyses—We calculated Cronbach’s alpha for men and women separately to
demonstrate internal consistency. To examine the validity of the 30-day recall period and
test-retest reliability, we conducted a separate 30-day diary study in 202 men and women for
whom we did not expect changes over the month.23 To express the consistency of scores
over time, we report intraclass correlations coefficients (ICCs) and their corresponding 95%
confidence intervals (CIs) for two administrations of the measure, one month apart.
Results
Psychometric Evaluation
A summary of fit statistics is shown in Table 2. We expect future data collection efforts will
allow for calibration of the Orgasm and Anal Discomfort subdomains, but there were not
enough responses (Anal Discomfort) or items (Orgasm) to support calibration at present. For
the other domains, all calibrated items satisfied the basic assumptions for adequate
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distribution (none displayed sparseness or monotonicity and higher item scores
corresponded to higher scale sum-scores). All calibrated item banks had high comparative fit
indices, supporting unidimensional models, though some lack of fit was suggested by the
RMSEA. With rare exception, items had factor loading and polyserial correlation of 0.8 or
greater. Item properties (from item calibration) are available online.24
DIF
For DIF analysis by survey mode (phone versus internet), there was mode equivalence (i.e.,
no DIF) between phone and internet surveys at both the domain- and item-level; however,
the multiple group models failed to converge for the Vaginal Discomfort and Erectile
Function domains due to inadequate sample size. For Satisfaction, many of the likelihood-
ratio tests from ordinal logistic regression were significant for DIF (p < 0.001); however, the
effect sizes were small and did not reach the pre-specified 0.130 cut-point, tempering the
finding of differences in item response by gender. Multiple-group and graphical analyses
confirmed the lack of noticeable DIF. The intraclass correlation between the factor scores
predicted by the common and sex-specific IRT models was greater than 0.99, which
reflected an almost perfect psychometric agreement between males and females. For Interest
in Sexual Activity, none of the items displayed significant DIF by the ordinal logistic
regression method, though the multiple-group analysis suggested possible DIF. Graphical
analyses did not reveal any substantial DIF, though the ICC between the factor scores
predicted by the common and gender-specific IRT models was 0.88. This ambiguity
regarding gender-related DIF for Interest in Sexual Activity suggests the need for more
research.
Scoring
Calibrated subdomain scores are expressed as T scores (mean = 50, standard deviation= 10).
A T score of 50 corresponds to the mean response among the cancer survivors used for item
testing. Higher scores corresponded to higher levels of the item or domain.
Administration
All items in the PROMIS SexFS item banks are not intended to be administered together,
but rather that researchers should have the flexibility to select the items that are relevant to
their specific sample. For the calibrated scales, if one or more items from within that
instrument are administered, a respondent’s score will be calculated using IRT parameters
(either through the PROMIS Assessment Center or look-up tables provided in the user
manual). For the 6 non-calibrated item banks (e.g., Interfering Factors), the items within
those instruments are not combined in any way to create a score. Each item in these
instruments measures a very specific construct corresponding only to that item (e.g., how
much has fatigue affected satisfaction with sex life). For any given item in these
uncalibrated instruments, the researcher can use the raw item responses directly for analyses.
In addition to the full banks, from which researchers can select items, we produced a brief
“off the shelf” measure, the PROMIS Sexual Function and Satisfaction Brief Profile. It
includes 1 to 3 of the best general-purpose items from each of the key domains of sexual
function (8 total items for men, 10 for women).
Validity
In general, the correlations between subdomains of the PROMIS SexFS and the
corresponding subdomains of the FSFI and IIEF provide strong evidence for the construct
validity of the PROMIS SexFS and the brief profile measures (Table 3). Additionally,
patients who had asked a provider for help with sexual problems were significantly different
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from those who had not asked and in the directions we expected (Table 4). Askers had
significantly greater interest in sexual activity, increased vaginal discomfort, and lower
levels of erectile function, lubrication, orgasm, and overall satisfaction. These effect sizes
were greater than or equal to the effects for the corresponding subscales of the FSFI and
IIEF. In three cases, the PROMIS SexFS and brief profiles detected statistically significant
(p<.05) differences between those who did and did not ask, whereas the FSFI or IIEF did
not.
Reliability
Estimates of internal consistency (Cronbach’s alpha) were calculated separately for men and
women and were high, ranging from 0.87–0.95 (Table 5). Test-retest reliability was also
favorable, based on intraclass correlation coefficients (ranging from 0.71–0.87).
Discussion
The PROMIS SexFS is a customizable self-reported measure of sexual function with
demonstrated validity for use in cancer populations. Version 1.0 consists of 11 domains. It
has 79 items in 5 calibrated scales (Interest in Sexual Activity, Lubrication [women],
Vaginal Discomfort [women], Erectile Function [men], Global Satisfaction with Sex Life)
and 6 collections of stand-alone items (Sexual Activities, Orgasm, Interfering Factors,
Therapeutic Aids, Anal Discomfort, Screener Items). The PROMIS SexFS instruments are
available for download on the Assessment Center™ website (http://assessmentcenter.net/).
The PROMIS SexFS offers researchers an outcome measure for use with men and women
with common domains where possible (e.g., Satisfaction). It allows researchers to record
frequencies of specific sexual activities but does not generally refer to specific activities
when measuring function, making it neutral to the respondent’s partner status or sexual
orientation. It offers a group of items (Interfering Factors) to capture reasons for respondent
dissatisfaction with sex life. This greater conceptual precision in understanding the problems
experienced by individuals could lead to more focused interventions.
While it was developed primarily as an outcome measure, the PROMIS SexFS may offer
benefit when used in clinical practice. For instance, screening patients for sexual problems
or tracking the trajectory of patients’ sexual activities, function, satisfaction, and/or use of
therapeutic aids could help practitioners identify patients who may be in need of intervention
or treatment. Administering this measure may also provide psycho-educational value by
helping patients to rate and track their sexual satisfaction and to identify specific aspects of
sexual function that they wish to improve in order to increase the quality of their sexual
lives. Finally, clinicians may find that offering their patients the opportunity to report on
their sexual function and satisfaction in a confidential manner will facilitate conversations
with patients about this sensitive topic.
Most PROMIS SexFS items are not specific to cancer but have thus far only been validated
in cancer samples. However, we designed the measure to accommodate various health states
or conditions that could affect sexual function. Ongoing research is currently testing the
PROMIS SexFS measure in other targeted groups (e.g., adults with diabetes, heart disease,
anxiety, depression, age >65, lesbian, gay, or bisexual, as well as a nationally representative
sample of U.S. adults). We are also testing the expansion of the existing domains (e.g.,
Orgasm), and the addition of new domains (e.g., subjective arousal, oral discomfort, and
vulvar discomfort)..
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The PROMIS SexFS measures version 1.0 offer researchers a reliable and valid tool to
measure self-reported sexual function and satisfaction among diverse men and women with
cancer. The measure is customizable in that researchers can select the relevant SexFS
domains and items comprising those domains for their study. The measures are
comprehensive in scope, covering both physical and psychological components. They are
broadly applicable with respect to age, gender, sexual orientation, partner status, and literacy
level. Finally, they are disease-neutral yet also able to capture relevant symptoms of cancer
and its treatment that interfere with sexual satisfaction. These features should enhance our
ability to describe and intervene on specific aspects of the sexual function and satisfaction of
patients with cancer.
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Figure. Conceptual Measurement Model of Sexual Function And Related Domains
Adapted from Flynn KE, Jeffery DD, Keefe FJ, et al. Sexual functioning along the cancer
continuum: focus group results from the Patient-Reported Outcomes Measurement
Information System (PROMIS). Psycho-Oncology. Apr 2011;20(4):378–386.
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Table 1
Characteristics of Patients in Item Testing Sample (n = 819)
Characteristic Total (n = 819) Men (n = 389) Women (n = 430)
Age, mean ± SD, y 58.5 ± 11.8 61.4 ± 10.8 55.9 ± 12.2
Age group, No. (%)
 ≤ 40 years 59 (7) 14 (4) 45 (10)
 41 to 50 years 127 (16) 29 (7) 98 (23)
 51 to 64 years 377 (46) 197 (51) 180 (42)
 65 to 79 years 232 (28) 134 (35) 98 (23)
 ≥ 80 years 21 (3) 13 (3) 8 (2)
Race, No. (%)
 Black or African American 80 (10) 39 (10) 41 (10)
 American Indian/Alaska Native 10 (1) 6 (2) 4 (<1)
 Asian 12 (1) 2 (<1) 10 (2)
 Native Hawaiian/Other Pacific Islander 10 (1) 1 (<1) 1 (<1)
 White 705 (87) 338 (87) 367 (86)
 Multiple races or other 2 (< 1) 1 (<1) 5 (1)
Hispanic or Latino ethnicity, No. (%) 21 (3) 10 (3) 11 (3)
Educational attainment, No. (%)
 Less than high school 21 (3) 14 (4) 10 (2)
 High school graduate/GED 100 (12) 35 (9) 65 (15)
 Some college 255 (31) 122 (31) 133 (31)
 College degree 229 (28) 114 (29) 115 (27)
 Advanced degree (MA, PhD, MD) 211 (26) 104 (27) 107 (25)
Treatment status in past month, No. (%)
 None (ie, posttreatment follow-up) 526 (64) 290 (75) 236 (55)
 Undergoing treatment 290 (36) 98 (25) 192 (45)
 Radiation therapy 29 (10) 15 (4) 14 (3)
 Hormonal therapy (eg, tamoxifen, anastrozole, leuprolide) 140 (48) 28 (7) 112 (26)
 Chemotherapy (injection or oral) 116 (40) 46 (12) 70 (16)
 Immunotherapy (eg, interferon) 9 (3) 2 (<1) 7 (2)
 Other 36 (12) 17 (4) 19 (4)
Recurrence of cancer, No. (%) 151 (18) 68 (17) 83 (19)
Cancer spread to lymph nodes, No. (%) 202 (25) 68 (17) 134 (31)
Cancer spread to another area, No. (%) 134 (16) 57 (15) 77 (18)
Primary cancer diagnosis, No. (%)
 Bone/muscle cancer 14 (2) 6 (2) 8 (2)
 Brain cancer 4 (< 1) 3 (<1) 1 (<1)
 Breast cancer 252 (35) 1 (<1) 251 (62)
 Colorectal 98(13) 57 (18) 41 (10)
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Characteristic Total (n = 819) Men (n = 389) Women (n = 430)
 Esophageal or stomach cancer 17 (2) 13 (4) 4 (<1)
 Gynecologic cancer 29 (4) -- 29 (7)
 Head/neck cancer 9 (< 1) 5 (2) 4 (<1)
 Hodgkin lymphoma 23 (3) 7 (2) 16 (4)
 Leukemia 20 (3) 12 (4) 8 (2)
 Liver cancer 3 (< 1) 1 (<1) 2 (<1)
 Lung cancer 56 (8) 35 (11) 21 (5)
 Melanoma 4 (< 1) 2 (<1) 2 (<1)
 Multiple Myeloma 2 (< 1) 2 (<1) --
 Non-Hodgkin lymphoma 12 (2) 7 (2) 5 (1)
 Pancreatic cancer 5 (< 1) 3 (<1) 2 (<1)
 Prostate cancer 146 (20) 146 (45) --
 Urologic cancer 23 (3) 16 (5) 7 (2)
 Unknown or Other 9 (1) 6 (2) 3 (<1)
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Table 2
Fit Indices for Confirmatory Factor Analysis of Calibrated Subdomains
Instrument Name # of items CFI TLI RMSEA
Global Satisfaction with Sex Life 7 0.983 0.976 0.168
Interest in Sexual Activity 4 0.998 0.995 0.129
Lubrication 8 0.985 0.979 0.187
Vaginal Discomfort 10 0.993 0.991 0.124
Erectile Function 8 0.988 0.986 0.134
Abbreviation: CFI, comparative fit index; TLI, Tuker-Lewis index; RMSEA, root-mean-square error of approximation.
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Table 3
Correlations between PROMIS Sexual Function and Satisfaction Full Bank and Brief Profile Subdomains and
Corresponding Measures
Women (n = 430) Men (n = 388)
Measures r* Measures r*
PROMIS Interest in Sexual Activity
0.84 (0.82)
PROMIS Interest in Sexual Activity
0.82 (0.79)
FSFI† Desire IIEF‡ Desire













FSFI Orgasm IIEF Orgasmic Function
PROMIS Global Satisfaction with Sex Life
0.76 (0.62)
PROMIS Global Satisfaction with Sex Life
0.82 (0.66)
FSFI Satisfaction IIEF Overall Satisfaction
IIEF Intercourse Satisfaction 0.75 (0.68)




Female Sexual Function Index
‡
International Index of Erectile Function
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Table 5











(Brief Profile) (n =
101)
PROMIS Interest in Sexual Activity 0.89 0.77 (0.72) 0.87 0.71 (0.65)*
PROMIS Lubrication 0.95 0.87 (0.87)
PROMIS Vaginal Discomfort 0.94 0.80 (0.75)
PROMIS Erectile Function 0.92 0.87 (0.77)
PROMIS Global Satisfaction with Sex
Life
0.93 0.75 (0.69) 0.92 0.74 (0.66)
*
Numbers reflect the deletion of a single outlier with a “5” at first administration and a “1” at second administration. Inclusion of the outlier results
in ICCs of 0.55 and 0.54 for the full bank and brief profile measures, respectively.
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